Prognostic implications of C-reactive protein and troponin following percutaneous coronary intervention

Canadian Journal of Cardiology

Volumn 25, Issue 2, 2009, Pages

  Hubacek, Jaroslav ^a   Basran, Rashpal S ^b   Shrive, Fiona M ^a   Shewchuk, Lana ^a   Goodhart, David M ^a   Anderson, Todd J ^a,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c NONE   (Canada)

Author keywords

Angioplasty; Inflammation; Myocardial infarction; Statins

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN T; BIOLOGICAL MARKER; HYPOCHOLESTEROLEMIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CONTROLLED STUDY; CORONARY STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE NECROSIS; HUMAN; INTRACARDIAC THROMBOSIS; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PROGNOSIS; BLOOD; CONFIDENCE INTERVAL; HEART MUSCLE; INFLAMMATION; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; RISK; STATISTICAL MODEL; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIUM; ODDS RATIO; PROGNOSIS; TIME FACTORS; TROPONIN T;

EID: 63049102320     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(09)70483-0     Document Type: Article

References (27)

1. Cavallini C, Savonitto S, Violini R, et at. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: Results of the CK-MB and PCI study. Eur Heart J 2005;26:1494-8.
2. Braunwald E, Antman EM, Beasley JW, et A. ACC/AHA Guideline Update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary Article: A report of the American College of Cardiology/American Heart Association Task Force on ractice Guidelines (Committee on the Management of ents With Unstable Angina). Circulation 2002;106:1893-900.
3. Bolognese L, Duccl K, Angioli P et al. Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2004;110:1592-7.
4. Selvanayagam JB, Porto I, Channon K, et al. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury; Insights from cardiovascular magnetic resonance imaging. Circulation 2005; 111: 1027-32.
5. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
6. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997;349:462-6.
7. Heeschen C, Hamm CW, Bruemmer J, Simoons ML, for the CAPTURE Investigator. Predictive value of C-reactive protein and troponin T in patients with unstable angina: A comparative analysis. J Am Coll Cardiol 2000;35:1535-42.
8. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L, for the FRISC Study Group. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 2000;343:1139-47.
9. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy. J Am Coll Cardiol 1998;31:1460-5.
10. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-44.
11. Ridker PM, Cannon CP, Morrow D, et al, C-reactive protein levels and outcomes after statin therapy. New Engl J Med 2005;352:20-8.
12. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
13. Herrmann J, von Birgelen C, Haude M, et al. Prognostic implication of cardiac troponin T increase following srent implantation. Heart 2002;87:549-53.
14. Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR Jr, Rihal CS. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. J Am Coll Cardiol 2006;48:1765-70.
15. Natarajan MK, Kreatsoulas C, Velianou JL, Mehta SR, Pericak D, Goodhart DM. Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions. Am J Cardiol 2004;93:750,3.
16. Fuchs S, Kornowski R, Mehran R, et al. Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. Am J Cardiol 2000;85:1077-82.
17. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. New Engl J Med 1997;337:1648-53.
18. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999;34:1512-21.
19. Chew DP, Bhatt DL, Robbins MA, et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001;104:992-7.
20. Walter DH, Fichtlscheret S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001;37:839-46.
21. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9.
22. Briguori C, Colombo A, Airoldi F, et al. Statin administration before percutaneous coronary intervention: Impact on periprocedural myocardial infarction. Eur Heart J 2004;25:1822-8.
23. Chan AW, Bhatt DL, Chew DP, et al. Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 2003;107:1750-6.
24. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-8.
25. Kinlay S, Schwartz GG, Olsson AG, et al. Higli-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 200;108:1560-6.
26. Cantor WJ, Newby LK, Christenson RH, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002;39:1738-44.
27. Nallamothu BK, Chetcuti S, Mukherjee D, et al. Prognostic implication of troponin I elevation after percutaneous coronary intervention. Am J Cardiol 2003;91:1272-4.